An Exploratory Study of Ixabepilone Administered as an Enteric Coated Formulation in Patients With Advanced Cancer.
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the action of Ixabepilone in the body over a period of time including the process of absorption, distribution, metabolism and elimination.
United States: Food and Drug Administration
|Local Institution||Washington, District of Columbia|
|Local Institution||Detroit, Michigan|